Inotek Pharmaceuticals Corp Share Price Nasdaq
Equities
US45780V1026
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- | - |
10/05 | UBS Adjusts Rocket Pharmaceuticals Price Target to $51 From $54, Maintains Buy Rating | MT |
10/05 | Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise | MT |
Sales 2024 * | 26.32M 0 2.2B | Sales 2025 * | 163M 0 13.6B | Capitalization | 2.15B 0 179B |
---|---|---|---|---|---|
Net income 2024 * | -260M - -21.68B | Net income 2025 * | -219M - -18.26B | EV / Sales 2024 * | 74.3 x |
Net cash position 2024 * | 193M 0 16.1B | Net cash position 2025 * | 111M 0 9.3B | EV / Sales 2025 * | 12.5 x |
P/E ratio 2024 * |
-8.78
x | P/E ratio 2025 * |
-11.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.69% |
Latest transcript on Inotek Pharmaceuticals Corp
Managers | Title | Age | Since |
---|---|---|---|
Gaurav D. Shah
CEO | Chief Executive Officer | 49 | 04/18/04 |
Kinnari Patel
PSD | President | 46 | 04/18/04 |
Chief Tech/Sci/R&D Officer | 60 | 01/16/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pedro Granadillo
BRD | Director/Board Member | 77 | 04/18/04 |
Carsten Boess
BRD | Director/Board Member | 57 | 01/16/01 |
David Southwell
BRD | Director/Board Member | 63 | 01/14/01 |
1st Jan change | Capi. | |
---|---|---|
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |